Source comparison
Tesamorelin + Ipamorelin Blend: Mechanism Comparison
Receptor Target GHRH receptors (anterior pituitary somatotrophs) Ghrelin receptors (GHS-R1a, hypothalamus + pituitary) Dual activation: GHRH + ghrelin pathways Simultaneous receptor activation produces non-additive synergy Primary Action Stimulates GH synthesi
This comparison does not assign a generated winner or score.
- Receptor Target
- GHRH receptors (anterior pituitary somatotrophs)
- Ghrelin receptors (GHS-R1a, hypothalamus + pituitary)
- Dual activation: GHRH + ghrelin pathways
- Simultaneous receptor activation produces non-additive synergy
- Primary Action
- Stimulates GH synthesis and pulsatile release via cAMP-PKA-CREB
- Suppresses somatostatin, removes inhibitory brake on GH release
- Amplified GH pulse: synthesis stimulus + brake removal
- The blend creates 2.8–3.5× higher GH peaks than either compound independently
- Peak GH Concentration
- 8–15 ng/mL at 60–90 min (2mg dose)
- 4–8 ng/mL at 20–30 min (200–300 mcg dose)
- 18–28 ng/mL at 60–90 min
- Synergistic GH elevation triggers supraphysiological lipolysis
- VAT Reduction (26 weeks)
- 15–18% (EGRIFTA trial data)
- 6–9% (limited monotherapy data)
- 22–27% (parallel research protocol estimates)
- The blend produces VAT loss exceeding the sum of individual effects
- Timing Sensitivity
- Moderate. Pulse occurs 60–90 min post-dose
- High. Somatostatin suppression peaks 20–30 min post-dose
- Critical. Must dose within 15 min of each other
- Administering compounds >45 min apart loses 40–60% of synergy